Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price17.75 USD
Fair value21.92
Ethical score83.8/100
RatingOPPORTUNITY
Our investment reviews on this name
2026-09-03Read Markdown19.06-6.9% to today ✓
2026-07-02Read Accumulation17.71+0.2% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Kenvue holds its Markdown at $17.75. The statistical read favours the buyers, held for 4 days.
As held on the ledger · 2026-09-09
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 4 days
Price at the screen
$17.75
Valuation
20.88 trailing · 14.30 forward price to earnings
Values screen
PASS· score 83.8
Beta
0.43
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.04%
Below 33%
Interest-bearing debt is just 32.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
12.72%
Below 49%
Money owed to the company is 12.7% of assets, under the 49% limit.
Pass
Revenue purity
0.34%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 24% discount to our $21.92 fair value, moderate competitive moat, 3.00% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 23.5% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Hold. The average target sits +7% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Daily Health Brands at a Quiet Discount
Think of the last time you grabbed a painkiller or a skin cream off the shelf. Kenvue sits behind many of those everyday items across three steady segments. The shares sit at $18.98 against our $22.15 fair value, a 17 percent margin that the market has yet to close.
Revenue edges up 4 percent, the 11 percent profit margin and 16 percent ROE look solid for this defensive patch, and the moderate moat plus clean ethical screen keep the business attractive on a 15.3 times forward multiple. Analysts sit on hold with a $20 median target, yet the gap to our number still marks a clear opportunity.
Slow top-line growth leaves little room for error if costs rise or shelf space shrinks, and the hold rating shows the street wants more proof before it moves. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KVUE trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-03Markdown · changed$19.06-2.2%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 12%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (11 analysts) rates it hold, with a mean price target of $19.
2026-08-04Accumulation$19.48+10.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 10.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 12%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (11 analysts) rates it hold, with a mean price target of $19.
2026-07-18Accumulation$17.71+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 12%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (11 analysts) rates it hold, with a mean price target of $19.
2026-07-03Accumulation$17.71+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$17.71Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.